Novanta Announces Financial Results for the Third Quarter 2024
Novanta (NOVT) reported strong Q3 2024 financial results with GAAP revenue of $244.4 million, up 10.3% year-over-year. The company posted GAAP net income of $19.2 million and diluted EPS of $0.53. Acquisition activities contributed 9.5% to revenue growth, while organic revenue growth was flat. The company's minimally invasive surgery products achieved a book-to-bill ratio of 1.4. For Q4 2024, Novanta expects revenue between $237-242 million and projects full-year 2024 revenue of $948-953 million. The company anticipates organic revenue growth of up to 10% in 2025.
Novanta (NOVT) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con un fatturato GAAP di 244,4 milioni di dollari, in aumento del 10,3% rispetto all'anno precedente. L'azienda ha registrato un utile netto GAAP di 19,2 milioni di dollari e un EPS diluito di 0,53 dollari. Le attività di acquisizione hanno contribuito per il 9,5% alla crescita del fatturato, mentre la crescita del fatturato organico è rimasta stabile. I prodotti per interventi chirurgici minimamente invasivi della società hanno raggiunto un rapporto book-to-bill di 1,4. Per il quarto trimestre del 2024, Novanta prevede un fatturato compreso tra 237 e 242 milioni di dollari e prevede un fatturato per l'intero anno 2024 di 948-953 milioni di dollari. L'azienda anticipa una crescita del fatturato organico fino al 10% nel 2025.
Novanta (NOVT) informó sobre resultados financieros sólidos para el tercer trimestre de 2024, con un ingreso GAAP de 244,4 millones de dólares, un aumento del 10,3% en comparación con el año anterior. La compañía reportó un ingreso neto GAAP de 19,2 millones de dólares y un EPS diluido de 0,53 dólares. Las actividades de adquisición contribuyeron con un 9,5% al crecimiento de ingresos, mientras que el crecimiento de ingresos orgánicos se mantuvo plano. Los productos de cirugía mínimamente invasiva de la empresa lograron una relación book-to-bill de 1,4. Para el cuarto trimestre de 2024, Novanta espera ingresos entre 237 y 242 millones de dólares y proyecta ingresos anuales de 948-953 millones de dólares para 2024. La compañía anticipa un crecimiento de ingresos orgánicos de hasta el 10% en 2025.
노반타 (NOVT)는 2024년 3분기 강력한 재무 실적을 보고했으며, GAAP 수익은 2억 4천440만 달러로 전년 대비 10.3% 증가했습니다. 이 회사는 GAAP 순이익 1천920만 달러와 희석 주당순이익(EPS) 0.53달러를 기록했습니다. 인수 활동이 수익 성장에 9.5% 기여했으며, 유기적 수익 성장률은 정체 상태였습니다. 회사의 최소 침습 수술 제품은 1.4의 매출 대비 출하 비율을 달성했습니다. 2024년 4분기에는 2억 3천7백만에서 2억 4천2백만 달러 사이의 수익을 예상하며, 2024년 전체 연간 수익은 9억 4천8백만에서 9억 5천3백만 달러가 될 것으로 전망하고 있습니다. 회사는 2025년까지 최대 10%의 유기적 수익 성장을 예상하고 있습니다.
Novanta (NOVT) a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec un chiffre d'affaires GAAP de 244,4 millions de dollars, en hausse de 10,3 % par rapport à l'année précédente. L'entreprise a enregistré un bénéfice net GAAP de 19,2 millions de dollars et un bénéfice par action dilué de 0,53 dollar. Les activités d'acquisition ont contribué à hauteur de 9,5 % à la croissance des revenus, tandis que la croissance organique est restée stable. Les produits de chirurgie peu invasive de l'entreprise ont atteint un taux book-to-bill de 1,4. Pour le quatrième trimestre 2024, Novanta prévoit un chiffre d'affaires compris entre 237 et 242 millions de dollars et prévoit un chiffre d'affaires annuel de 948 à 953 millions de dollars pour 2024. L'entreprise anticipe une croissance organique des revenus pouvant atteindre 10 % en 2025.
Novanta (NOVT) berichtete über starke finanzielle Ergebnisse für das dritte Quartal 2024 mit einem GAAP-Umsatz von 244,4 Millionen US-Dollar, was einem Anstieg von 10,3 % im Jahresvergleich entspricht. Das Unternehmen verzeichnete GAAP-Nettoeinkünfte von 19,2 Millionen US-Dollar und verwässertes EPS von 0,53 US-Dollar. Akquisitionsaktivitäten trugen mit 9,5 % zum Umsatzwachstum bei, während das organische Umsatzwachstum stabil blieb. Die minimalinvasiven chirurgischen Produkte des Unternehmens erreichten ein Verhältnis von Buch zu Rechnung von 1,4. Für das vierte Quartal 2024 erwartet Novanta einen Umsatz zwischen 237 und 242 Millionen US-Dollar und prognostiziert für das gesamte Jahr 2024 einen Umsatz von 948 bis 953 Millionen US-Dollar. Das Unternehmen geht von einem organischen Umsatzwachstum von bis zu 10 % im Jahr 2025 aus.
- Revenue increased 10.3% YoY to $244.4 million
- Customer bookings increased 13% YoY for core businesses
- Minimally invasive surgery products achieved 1.4 book-to-bill ratio
- Adjusted EBITDA improved to $57.0 million from $52.2 million YoY
- Company projects up to 10% organic revenue growth for 2025
- GAAP net income decreased to $19.2 million from $21.2 million YoY
- GAAP diluted EPS declined to $0.53 from $0.59 YoY
- Operating cash flow decreased to $23.0 million from $44.6 million YoY
- Organic Revenue Growth was flat at 0.0% for Q3 2024
Insights
The Q3 results show mixed performance with notable strengths and challenges. Revenue grew
Profitability metrics present a nuanced picture: GAAP operating income increased to
The company's strategic positioning in medical and advanced technology equipment manufacturing shows resilience despite macroeconomic headwinds affecting capital equipment purchases. The 13% year-over-year increase in core business bookings indicates strong market demand fundamentals. The focus on new product launches and the Novanta Growth System operating model demonstrates a solid foundation for future growth.
The guidance for full-year 2024 revenue of
-
Third Quarter 2024 GAAP Revenue of
$244 million -
Third Quarter 2024 GAAP Net Income of
$19 million -
Third Quarter 2024 GAAP Diluted Earnings Per Share of
$0.53 -
Third Quarter 2024 Adjusted Earnings Per Share of
$0.85 -
Third Quarter 2024 Adjusted EBITDA of
$57 million
Financial Highlights |
Three Months Ended |
|
|||||
(In millions, except per share amounts) |
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
GAAP |
|
|
|
|
|
||
Revenue |
$ |
244.4 |
|
|
$ |
221.5 |
|
Operating Income |
$ |
32.6 |
|
|
$ |
30.3 |
|
Net Income |
$ |
19.2 |
|
|
$ |
21.2 |
|
Diluted EPS |
$ |
0.53 |
|
|
$ |
0.59 |
|
Non-GAAP* |
|
|
|
|
|
||
Adjusted Operating Income |
$ |
46.8 |
|
|
$ |
43.0 |
|
Adjusted Diluted EPS |
$ |
0.85 |
|
|
$ |
0.85 |
|
Adjusted EBITDA |
$ |
57.0 |
|
|
$ |
52.2 |
|
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.
“Our team delivered strong third quarter results, at the top end of our guidance range, driven by the strength of our diversified business and the Novanta Growth System operating model,” said Matthijs Glastra, Chair and Chief Executive Officer. “The third quarter demonstrated continued sequential improvement in our revenue growth rate, and customer bookings increased
Third Quarter
During the third quarter of 2024, Novanta generated GAAP revenue of
In the third quarter of 2024, GAAP operating income was
Adjusted Diluted EPS was
Operating cash flow for the third quarter of 2024 was
Financial Guidance
“While the macroeconomic environment throughout 2024 created some challenging dynamics with the timing of capital equipment purchases in the year, we believe we are well-positioned to benefit from a recovering investment climate in 2025 and beyond. Our Novanta team and our customers both remain committed to driving positive momentum from new product launches, which we believe will result in an improving and accelerating revenue and profit growth in 2025. Based on our customers’ expectations, backlog, and product launches, we expect Organic Revenue growth of up to
For the fourth quarter of 2024, the Company expects GAAP revenue of approximately
For the full year 2024, the Company expects GAAP revenue of approximately
Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses; foreign exchange gains/(losses); significant discrete income tax expenses (benefits); benefits or expenses associated with the completion of tax audits; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below.
Conference Call Information
The Company will host a conference call on Tuesday, November 5, 2024 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Wednesday, January 1, 2025.
Use of Non-GAAP Financial Measures
The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Net Income, and Net Debt.
The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to determine bonus payments for senior management and employees. The Company has also used in the past, and may use in the future, Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.
Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.
Safe Harbor and Forward-Looking Information
Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the full years 2024 and 2025 and fourth quarter of 2024; expectations for our end markets and market position; macroeconomic expectations; our competitive position, including our positioning for long-term growth, capital spending and momentum from new product launches; and other statements that are not historical facts.
These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with epidemics, pandemics or other public health crises; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and
Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.
About Novanta
Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”
More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.
NOVANTA INC. |
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
|
Three Months Ended |
|
|||||
|
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
Revenue |
$ |
244,405 |
|
|
$ |
221,503 |
|
Cost of revenue |
|
135,190 |
|
|
|
119,912 |
|
Gross profit |
|
109,215 |
|
|
|
101,591 |
|
Operating expenses: |
|
|
|
|
|
||
Research and development and engineering |
|
23,253 |
|
|
|
22,022 |
|
Selling, general and administrative |
|
44,319 |
|
|
|
39,648 |
|
Amortization of purchased intangible assets |
|
6,589 |
|
|
|
5,131 |
|
Restructuring, acquisition, and related costs |
|
2,499 |
|
|
|
4,481 |
|
Total operating expenses |
|
76,660 |
|
|
|
71,282 |
|
Operating income |
|
32,555 |
|
|
|
30,309 |
|
Interest income (expense), net |
|
(8,079 |
) |
|
|
(6,756 |
) |
Foreign exchange transaction gains (losses), net |
|
(202 |
) |
|
|
(370 |
) |
Other income (expense), net |
|
(49 |
) |
|
|
(189 |
) |
Income before income taxes |
|
24,225 |
|
|
|
22,994 |
|
Income tax provision (benefit) |
|
5,033 |
|
|
|
1,771 |
|
Net Income |
$ |
19,192 |
|
|
$ |
21,223 |
|
|
|
|
|
|
|
||
Earnings per common share: |
|
|
|
|
|
||
Basic |
$ |
0.53 |
|
|
$ |
0.59 |
|
Diluted |
$ |
0.53 |
|
|
$ |
0.59 |
|
|
|
|
|
|
|
||
Weighted average common shares outstanding—basic |
|
35,959 |
|
|
|
35,856 |
|
Weighted average common shares outstanding—diluted |
|
36,129 |
|
|
|
36,041 |
|
NOVANTA INC. |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
|
September 27, |
|
|
December 31, |
|
||
|
2024 |
|
|
2023 |
|
||
ASSETS |
|
|
|
|
|
||
Current Assets |
|
|
|
|
|
||
Cash and cash equivalents |
$ |
92,690 |
|
|
$ |
105,051 |
|
Accounts receivable, net |
|
164,502 |
|
|
|
139,410 |
|
Inventories |
|
154,021 |
|
|
|
149,371 |
|
Prepaid expenses and other current assets |
|
25,721 |
|
|
|
21,465 |
|
Total current assets |
|
436,934 |
|
|
|
415,297 |
|
Property, plant and equipment, net |
|
119,596 |
|
|
|
109,449 |
|
Operating lease assets |
|
44,645 |
|
|
|
38,302 |
|
Intangible assets, net |
|
198,394 |
|
|
|
145,022 |
|
Goodwill |
|
594,088 |
|
|
|
484,507 |
|
Other assets |
|
25,166 |
|
|
|
33,479 |
|
Total assets |
$ |
1,418,823 |
|
|
$ |
1,226,056 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
||
Current Liabilities |
|
|
|
|
|
||
Current portion of long-term debt |
$ |
5,016 |
|
|
$ |
4,968 |
|
Accounts payable |
|
68,720 |
|
|
|
57,195 |
|
Accrued expenses and other current liabilities |
|
82,864 |
|
|
|
77,012 |
|
Total current liabilities |
|
156,600 |
|
|
|
139,175 |
|
Long-term debt |
|
452,502 |
|
|
|
349,404 |
|
Operating lease liabilities |
|
42,672 |
|
|
|
37,345 |
|
Other long-term liabilities |
|
24,854 |
|
|
|
26,672 |
|
Total liabilities |
|
676,628 |
|
|
|
552,596 |
|
Stockholders’ Equity: |
|
|
|
|
|
||
Total stockholders’ equity |
|
742,195 |
|
|
|
673,460 |
|
Total liabilities and stockholders’ equity |
$ |
1,418,823 |
|
|
$ |
1,226,056 |
|
NOVANTA INC. |
|||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
|
Three Months Ended |
|
|||||
|
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
||
Net Income |
$ |
19,192 |
|
|
$ |
21,223 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
||
Depreciation and amortization |
|
14,155 |
|
|
|
11,397 |
|
Share-based compensation |
|
6,364 |
|
|
|
6,037 |
|
Deferred income taxes |
|
(4,197 |
) |
|
|
(4,663 |
) |
Other |
|
1,993 |
|
|
|
4,601 |
|
Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions: |
|
|
|
|
|
||
Accounts receivable |
|
(17,310 |
) |
|
|
193 |
|
Inventories |
|
7,002 |
|
|
|
4,442 |
|
Other operating assets and liabilities |
|
(4,173 |
) |
|
|
1,411 |
|
Net cash provided by (used in) operating activities |
|
23,026 |
|
|
|
44,641 |
|
Cash flows from investing activities: |
|
|
|
|
|
||
Purchases of property, plant and equipment |
|
(3,561 |
) |
|
|
(6,795 |
) |
Net cash provided by (used in) investing activities |
|
(3,561 |
) |
|
|
(6,795 |
) |
Cash flows from financing activities: |
|
|
|
|
|
||
Repayments under term loan and revolving credit facilities |
|
(28,639 |
) |
|
|
(51,549 |
) |
Payments of withholding taxes from share-based awards |
|
(63 |
) |
|
|
(163 |
) |
Other financing activities |
|
(179 |
) |
|
|
(252 |
) |
Net cash provided by (used in) financing activities |
|
(28,881 |
) |
|
|
(51,964 |
) |
Effect of exchange rates on cash and cash equivalents |
|
3,638 |
|
|
|
(1,251 |
) |
Increase (decrease) in cash and cash equivalents |
|
(5,778 |
) |
|
|
(15,369 |
) |
Cash and cash equivalents, beginning of period |
|
98,468 |
|
|
|
91,330 |
|
Cash and cash equivalents, end of period |
$ |
92,690 |
|
|
$ |
75,961 |
|
NOVANTA INC. |
|||||||
Revenue by Reportable Segment |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
|
Three Months Ended |
|
|||||
|
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
Revenue |
|
|
|
|
|
||
Precision Medicine and Manufacturing |
$ |
60,595 |
|
|
$ |
71,277 |
|
Medical Solutions |
|
103,783 |
|
|
|
83,378 |
|
Robotics and Automation |
|
80,027 |
|
|
|
66,848 |
|
Total |
$ |
244,405 |
|
|
$ |
221,503 |
|
NOVANTA INC. |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP): |
|||||||
|
Three Months Ended |
|
|||||
|
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
Precision Medicine and Manufacturing |
|
|
|
|
|
||
Gross Profit (GAAP) |
$ |
27,048 |
|
|
$ |
36,208 |
|
Gross Profit Margin (GAAP) |
|
44.6 |
% |
|
|
50.8 |
% |
Amortization of intangible assets |
|
503 |
|
|
|
585 |
|
Adjusted Gross Profit (Non-GAAP) |
$ |
27,551 |
|
|
$ |
36,793 |
|
Adjusted Gross Profit Margin (Non-GAAP) |
|
45.5 |
% |
|
|
51.6 |
% |
|
|
|
|
|
|
||
Medical Solutions |
|
|
|
|
|
||
Gross Profit (GAAP) |
$ |
42,373 |
|
|
$ |
34,027 |
|
Gross Profit Margin (GAAP) |
|
40.8 |
% |
|
|
40.8 |
% |
Amortization of intangible assets |
|
1,966 |
|
|
|
1,070 |
|
Adjusted Gross Profit (Non-GAAP) |
$ |
44,339 |
|
|
$ |
35,097 |
|
Adjusted Gross Profit Margin (Non-GAAP) |
|
42.7 |
% |
|
|
42.1 |
% |
|
|
|
|
|
|
||
Robotics and Automation |
|
|
|
|
|
||
Gross Profit (GAAP) |
$ |
40,569 |
|
|
$ |
32,652 |
|
Gross Profit Margin (GAAP) |
|
50.7 |
% |
|
|
48.8 |
% |
Amortization of intangible assets |
|
1,239 |
|
|
|
1,396 |
|
Adjusted Gross Profit (Non-GAAP) |
$ |
41,808 |
|
|
$ |
34,048 |
|
Adjusted Gross Profit Margin (Non-GAAP) |
|
52.2 |
% |
|
|
50.9 |
% |
|
|
|
|
|
|
||
Unallocated Corporate and Shared Services |
|
|
|
|
|
||
Gross Profit (GAAP) |
$ |
(775 |
) |
|
$ |
(1,296 |
) |
Adjusted Gross Profit (Non-GAAP) |
$ |
(775 |
) |
|
$ |
(1,296 |
) |
|
|
|
|
|
|
||
Novanta Inc. |
|
|
|
|
|
||
Gross Profit (GAAP) |
$ |
109,215 |
|
|
$ |
101,591 |
|
Gross Profit Margin (GAAP) |
|
44.7 |
% |
|
|
45.9 |
% |
Amortization of intangible assets |
|
3,708 |
|
|
|
3,051 |
|
Adjusted Gross Profit (Non-GAAP) |
$ |
112,923 |
|
|
$ |
104,642 |
|
Adjusted Gross Profit Margin (Non-GAAP) |
|
46.2 |
% |
|
|
47.2 |
% |
NOVANTA INC. |
|||||||||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||||||||||||||||||||||
(Amounts in thousands except per share amounts) |
|||||||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||||||
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP): |
|||||||||||||||||||||||||||
|
Three Months Ended September 27, 2024 |
|
|||||||||||||||||||||||||
|
Operating Income |
|
|
Operating Margin |
|
|
Income Before Income Taxes |
|
|
Income Tax Provision / (Benefit) |
|
|
Effective Tax Rate |
|
|
Net Income |
|
|
Diluted EPS |
|
|||||||
GAAP results |
$ |
32,555 |
|
|
|
13.3 |
% |
|
$ |
24,225 |
|
|
$ |
5,033 |
|
|
|
20.8 |
% |
|
$ |
19,192 |
|
|
$ |
0.53 |
|
Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Amortization of intangible assets |
|
10,297 |
|
|
|
4.2 |
% |
|
|
10,297 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Restructuring costs |
|
1,919 |
|
|
|
0.8 |
% |
|
|
1,919 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Acquisition and related costs |
|
580 |
|
|
|
0.2 |
% |
|
|
580 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Officer transition costs |
|
1,411 |
|
|
|
0.6 |
% |
|
|
1,411 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign exchange transaction (gains) losses, net |
|
|
|
|
|
|
|
202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Tax effect of non-GAAP adjustments |
|
|
|
|
|
|
|
|
|
|
2,903 |
|
|
|
|
|
|
|
|
|
|
||||||
Non-GAAP tax adjustments |
|
|
|
|
|
|
|
|
|
|
53 |
|
|
|
|
|
|
|
|
|
|
||||||
Total non-GAAP adjustments |
|
14,207 |
|
|
|
5.8 |
% |
|
|
14,409 |
|
|
|
2,956 |
|
|
|
|
|
|
11,453 |
|
|
|
0.32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Adjusted results (Non-GAAP) |
$ |
46,762 |
|
|
|
19.1 |
% |
|
$ |
38,634 |
|
|
$ |
7,989 |
|
|
|
20.7 |
% |
|
$ |
30,645 |
|
|
$ |
0.85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares outstanding - Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,129 |
|
||||||
NOVANTA INC. |
|||||||||||||||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||||||||||||||||||||||
(Amounts in thousands except per share amounts) |
|||||||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||||||
Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP): |
|||||||||||||||||||||||||||
|
Three Months Ended September 29, 2023 |
|
|||||||||||||||||||||||||
|
Operating Income |
|
|
Operating Margin |
|
|
Income Before Income Taxes |
|
|
Income Tax Provision / (Benefit) |
|
|
Effective Tax Rate |
|
|
Net Income |
|
|
Diluted EPS |
|
|||||||
GAAP results |
$ |
30,309 |
|
|
|
13.7 |
% |
|
$ |
22,994 |
|
|
$ |
1,771 |
|
|
|
7.7 |
% |
|
$ |
21,223 |
|
|
$ |
0.59 |
|
Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Amortization of intangible assets |
|
8,182 |
|
|
|
3.7 |
% |
|
|
8,182 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Restructuring costs |
|
4,330 |
|
|
|
2.0 |
% |
|
|
4,330 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Acquisition and related costs |
|
151 |
|
|
|
(0.0 |
)% |
|
|
151 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign exchange transaction (gains) losses, net |
|
|
|
|
|
|
|
370 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Tax effect on non-GAAP adjustments |
|
|
|
|
|
|
|
|
|
|
2,700 |
|
|
|
|
|
|
|
|
|
|
||||||
Non-GAAP tax adjustments |
|
|
|
|
|
|
|
|
|
|
770 |
|
|
|
|
|
|
|
|
|
|
||||||
Total non-GAAP adjustments |
|
12,663 |
|
|
|
5.7 |
% |
|
|
13,033 |
|
|
|
3,470 |
|
|
|
|
|
|
9,563 |
|
|
|
0.26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Adjusted results (Non-GAAP) |
$ |
42,972 |
|
|
|
19.4 |
% |
|
$ |
36,027 |
|
|
$ |
5,241 |
|
|
|
14.5 |
% |
|
$ |
30,786 |
|
|
$ |
0.85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares outstanding - Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,041 |
|
||||||
NOVANTA INC. |
|||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
|||||||
(In thousands of |
|||||||
(Unaudited) |
|||||||
Adjusted EBITDA (Non-GAAP): |
|||||||
|
Three Months Ended |
||||||
|
September 27, |
September 29, |
|||||
|
2024 |
2023 |
|||||
Net Income (GAAP) |
$ |
19,192 |
|
$ |
21,223 |
|
|
Net Income Margin |
7.9 |
% |
|
9.6 |
% |
||
Interest (income) expense, net |
8,079 |
6,756 |
|
||||
Income tax provision (benefit) |
5,033 |
|
1,771 |
|
|||
Depreciation and amortization |
14,155 |
|
|
11,397 |
|
||
Share-based compensation |
6,364 |
|
6,037 |
|
|||
Restructuring, acquisition and related costs |
2,491 |
|
4,481 |
|
|||
Officer transition costs |
1,411 |
— |
|
||||
Other, net |
251 |
559 |
|
||||
Adjusted EBITDA (Non-GAAP) |
$ |
56,976 |
|
$ |
52,224 |
|
|
Adjusted EBITDA Margin (Non-GAAP) |
23.3 |
% |
23.6 |
% |
|||
| Organic Revenue Growth (Non-GAAP): | |||
|
Three Months Ended September 27, 2024 |
|
|
|
Compared to |
|
|
|
Three Months Ended September 29, 2023 |
|
|
Reported Revenue Growth/(Decline) (GAAP) |
|
10.3 |
% |
Less: Change attributable to acquisitions |
|
9.5 |
% |
Plus: Change due to foreign currency |
|
(0.8 |
)% |
Organic Revenue Growth/(Decline) (Non-GAAP) |
|
0.0 |
% |
Net Debt (Non-GAAP): |
|||||||
|
September 27, |
|
|
December 31, |
|
||
|
2024 |
|
|
2023 |
|
||
Total Debt (GAAP) |
$ |
457,518 |
|
|
$ |
354,372 |
|
Plus: Deferred financing costs |
|
2,809 |
|
|
|
3,681 |
|
Gross Debt |
|
460,327 |
|
|
|
358,053 |
|
Less: Cash and cash equivalents |
|
(92,690 |
) |
|
|
(105,051 |
) |
Net Debt (Non-GAAP) |
$ |
367,637 |
|
|
$ |
253,002 |
|
Free Cash Flow (Non-GAAP): |
|||||||
|
Three Months Ended |
|
|||||
|
September 27, |
|
|
September 29, |
|
||
|
2024 |
|
|
2023 |
|
||
Net Cash Provided by Operating Activities (GAAP) |
$ |
23,026 |
|
|
$ |
44,641 |
|
Less: Purchases of property, plant and equipment |
|
(3,561 |
) |
|
|
(6,795 |
) |
Free Cash Flow (Non-GAAP) |
$ |
19,465 |
|
|
$ |
37,846 |
|
Net Income (GAAP) |
$ |
19,192 |
|
|
$ |
21,223 |
|
Net Cash Provided by Operating Activities as a Percentage of Net Income |
|
120.0 |
% |
|
|
210.3 |
% |
Free Cash Flow as a Percentage of Net Income |
|
101.4 |
% |
|
|
178.3 |
% |
Non-GAAP Financial Measures
The following provides additional explanations for non-GAAP financial measures used by the Company, including explanations for certain non-GAAP adjustments that may not be present in the quarterly disclosures included in the current earnings release but have been used by the Company in the two most recent fiscal years. See the tables above for the calculations of the non-GAAP financial measures used in this earnings release.
Organic Revenue Growth
The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees.
Adjusted Gross Profit and Adjusted Gross Profit Margin
The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin excludes amortization of acquired intangible assets because: (i) the amounts are non-cash; (ii) the Company cannot influence the timing and amount of future expense recognition; and (iii) excluding such expenses provides investors and management better visibility into the underlying trends and performance of our businesses.
Adjusted Operating Income and Adjusted Operating Margin
The calculation of Adjusted Operating Income and Adjusted Operating Margin excludes amortization of acquired intangible assets for the reasons described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The Company also excludes officer transition costs, restructuring, and acquisition and related costs due to the significant changes that have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Income Before Income Taxes
The calculation of Adjusted Income Before Income Taxes excludes amortization of acquired intangible assets, officer transition costs, and restructuring, and acquisition and related costs for the reasons described above for Adjusted Operating Income and Adjusted Operating Margin. The Company also excludes foreign exchange transaction gains (losses) from the calculation of Adjusted Income Before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate
Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable tax rates in effect for the respective jurisdictions and the income tax effect of non-GAAP adjustments discussed above. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions, tax audits, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate.
Adjusted Net Income
Because Income Before Income Taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets, officer transition costs, restructuring, acquisition and related costs, and foreign exchange transaction gains (losses) for the reasons described above for Adjusted Income Before Income Taxes. In addition, the Company excludes (i) significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (ii) the income tax effect of non-GAAP adjustments discussed above.
Adjusted Diluted EPS
Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted EPS excludes: (i) amortization of acquired intangible assets; (ii) officer transition costs; (iii) restructuring, acquisition and related costs; (iv) foreign exchange transaction gains (losses); (v) significant discrete income tax expenses (benefits) related to releases of valuation allowances, uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (vi) the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Net Income.
Adjusted EBITDA and Adjusted EBITDA Margin
The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, restructuring, acquisition and related costs, other non-operating (income) expense items, including foreign exchange transaction (gains) losses and net periodic pension costs of the Company’s frozen
Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.
In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation.
Free Cash Flow and Free Cash Flow as a Percentage of Net Income
The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of Net Income is defined as Free Cash Flow divided by Net Income. Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth.
Net Debt
The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105162002/en/
Novanta Inc.
Investor Relations:
Ray Nash
(781) 266-5137
Source: Novanta Inc.
FAQ
What was Novanta's (NOVT) revenue growth in Q3 2024?
What is Novanta's (NOVT) revenue guidance for full-year 2024?
What was Novanta's (NOVT) Q3 2024 earnings per share?
What is Novanta's (NOVT) organic growth projection for 2025?
